HRP20170091T1 - Dijagnostika interferona tip 1 - Google Patents
Dijagnostika interferona tip 1 Download PDFInfo
- Publication number
- HRP20170091T1 HRP20170091T1 HRP20170091TT HRP20170091T HRP20170091T1 HR P20170091 T1 HRP20170091 T1 HR P20170091T1 HR P20170091T T HRP20170091T T HR P20170091TT HR P20170091 T HRP20170091 T HR P20170091T HR P20170091 T1 HRP20170091 T1 HR P20170091T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- subject
- interferon
- mrna
- use according
- Prior art date
Links
- 102000014150 Interferons Human genes 0.000 title claims 3
- 108010050904 Interferons Proteins 0.000 title claims 3
- 229940079322 interferon Drugs 0.000 title claims 3
- 238000000034 method Methods 0.000 claims 9
- 230000001064 anti-interferon Effects 0.000 claims 8
- 108020004999 messenger RNA Proteins 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 108091034117 Oligonucleotide Proteins 0.000 claims 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 6
- 239000002299 complementary DNA Substances 0.000 claims 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 4
- 101000840275 Homo sapiens Interferon alpha-inducible protein 27, mitochondrial Proteins 0.000 claims 4
- 101000840293 Homo sapiens Interferon-induced protein 44 Proteins 0.000 claims 4
- 101000959664 Homo sapiens Interferon-induced protein 44-like Proteins 0.000 claims 4
- 101000657037 Homo sapiens Radical S-adenosyl methionine domain-containing protein 2 Proteins 0.000 claims 4
- 102100029604 Interferon alpha-inducible protein 27, mitochondrial Human genes 0.000 claims 4
- 102100029607 Interferon-induced protein 44 Human genes 0.000 claims 4
- 102100039953 Interferon-induced protein 44-like Human genes 0.000 claims 4
- 102100033749 Radical S-adenosyl methionine domain-containing protein 2 Human genes 0.000 claims 4
- 238000001514 detection method Methods 0.000 claims 4
- 206010025135 lupus erythematosus Diseases 0.000 claims 4
- 229950010077 sifalimumab Drugs 0.000 claims 4
- CBPNZQVSJQDFBE-HGVVHKDOSA-N temsirolimus Chemical group C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CCC2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-HGVVHKDOSA-N 0.000 claims 4
- 230000003321 amplification Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 238000002955 isolation Methods 0.000 claims 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 230000002194 synthesizing effect Effects 0.000 claims 2
- 108020004463 18S ribosomal RNA Proteins 0.000 claims 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 claims 1
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Claims (14)
1. Postupak za identificiranje subjekta koji je pogodan za liječenje lupusa s anti-interferonskim alfa protutijelom ili anti-interferonskim alfa receptorskim protutijelom koje modulira interferonsku aktivnost tip 1, koje obuhvaća otkrivanje povišene mRNK iz skupine gena koju čine IFI27, IFI44, IFI44L, i RSAD2 u uzorku od subjekta, pri čemu srednja višestruka promjena u mRNK iz skupine gena za barem četverostruki iznos označava subjekta koji je pogodan za liječenje lupusa s protutijelom, naznačen time da je povećanje u odnosu na
a) povećanje za uzorak iz tkiva ili osobe koja nema bolest, ili
b) ekspresiju jednog ili više kontrolnih gena.
2. Postupak prema zahtjevu 1, naznačen time da anti-interferonsko protutijelo je sifalimumab.
3. Postupak prema zahtjevu 1, naznačen time da anti-interferonsko protutijelo nije sifalimumab.
4. Postupak prema zahtjevu 1, naznačen time da otkrivanje mRNK za IFI27, IFI44, IFI44L, i RSAD2 sadrži
a) izoliranje RNK iz uzorka dobivenog od subjekta;
b) sintetiziranje cDNK iz RNK;
c) hibridiziranje cDNK s oligonukleotidima koji hibridiziraju u sekvence nukleinskih kiselina od SEQ ID NOs: 25 do 28 i 32; i
d) umnažanje cDNK i otkrivanje umnoženih proizvoda.
5. Postupak prema zahtjevu 4, naznačen time da su oligonukleotidi odabrani od oligonukleotida koji imaju sekvence iz SEQ ID NOs: 13 do 24.
6. Anti-interferonsko alfa protutijelo ili anti-interferonsko alfa receptorsko protutijelo koje modulira interferonsku aktivnost tip 1 za uporabu za liječenje lupusa kod pogodnog subjekta, naznačeno time da se subjekt koji je pogodan za liječenje identificira otkrivanjem povišene mRNK iz skupine gena koju čine IFI27, IFI44, IFI44L, i RSAD2 u uzorku od subjekta, pri čemu srednja višestruka promjena u mRNK iz skupine gena za barem četverostruki iznos označava subjekta koji je pogodan za liječenje lupusa, naznačeno time da je povećanje u odnosu na
a) povećanje za uzorak iz tkiva ili osobe koja nema bolest, ili
b) ekspresiju jednog ili više kontrolnih gena.
7. Protutijelo za uporabu prema zahtjevu 6, naznačeno time da anti-interferonsko protutijelo je sifalimumab.
8. Protutijelo za uporabu prema zahtjevu 6, naznačeno time da anti-interferonsko protutijelo nije sifalimumab.
9. Protutijelo za uporabu prema zahtjevu 6 naznačeno time da otkrivanje mRNK za IFI27, IFI44, IFI44L, i RSAD2 sadrži
a) izoliranje RNK iz uzorka dobivenog od subjekta;
b) sintetiziranje cDNK iz RNK;
c) hibridiziranje cDNK s oligonukleotidima koji hibridiziraju u sekvence nukleinskih kiselina od SEQ ID NOs: 25 do 28 i 32; i
d) umnažanje cDNK i otkrivanje umnoženih proizvoda.
10. Protutijelo za uporabu prema zahtjevu 9, naznačeno time da su oligonukleotidi odabrani od oligonukleotida koji imaju sekvence iz SEQ ID NOs: 13 do 24.
11. Postupak prema bilo kojem od zahtjeva 1 do 5 ili protutijelo za upotrebu prema bilo kojem od zahtjeva 6 do 10, naznačeni time da povećana mRNK je u odnosu na sakupljene uzorke od zdravih pacijenata.
12. Postupak prema bilo kojem od zahtjeva 1 b) ili 2 do 5 ili 11, u opsegu zahtjeva 2 do 5 i 11 koji se odnosi ponovno na zahtjev 1 b), ili protutijelo za upotrebu prema bilo kojem od zahtjeva 6b) ili 7 do 11, u opsegu zahtjeva 7 do 11 koji se odnosi ponovno na zahtjev 6b), naznačeni time da su kontrolni geni odabrani od ACTB, GAPDH, i 18S rRNK.
13. Postupak prema bilo kojem od zahtjeva 1 do 5, 11 ili 12 ili protutijelo za upotrebu prema bilo kojem od zahtjeva 6 do 12, naznačeni time da uzorak je cjelovita krv ili serum.
14. Postupak prema bilo kojem od zahtjeva 1 do 5, ili 11 do 13 ili protutijelo za upotrebu prema bilo kojem od zahtjeva 6 do 13, naznačeni time da je subjektu potrebno liječenje sistemskog eritemskog lupusa.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23963009P | 2009-09-03 | 2009-09-03 | |
PCT/US2010/047721 WO2011028933A1 (en) | 2009-09-03 | 2010-09-02 | Type 1 interferon diagnostic |
EP10814513.7A EP2473636B1 (en) | 2009-09-03 | 2010-09-02 | Type 1 interferon diagnostic |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20170091T1 true HRP20170091T1 (hr) | 2017-03-24 |
Family
ID=43649646
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20170091TT HRP20170091T1 (hr) | 2009-09-03 | 2017-01-19 | Dijagnostika interferona tip 1 |
Country Status (23)
Country | Link |
---|---|
US (3) | US20120251546A1 (hr) |
EP (1) | EP2473636B1 (hr) |
JP (2) | JP5727484B2 (hr) |
KR (1) | KR20120101340A (hr) |
CN (1) | CN102753704A (hr) |
AU (1) | AU2010289383B2 (hr) |
BR (1) | BR112012004781A2 (hr) |
CA (1) | CA2772921A1 (hr) |
CY (1) | CY1118566T1 (hr) |
DK (1) | DK2473636T3 (hr) |
ES (1) | ES2613055T3 (hr) |
HR (1) | HRP20170091T1 (hr) |
HU (1) | HUE032917T2 (hr) |
LT (1) | LT2473636T (hr) |
ME (1) | ME02599B (hr) |
MX (1) | MX2012002640A (hr) |
PL (1) | PL2473636T3 (hr) |
PT (1) | PT2473636T (hr) |
RS (1) | RS55641B1 (hr) |
RU (1) | RU2012112802A (hr) |
SI (1) | SI2473636T1 (hr) |
SM (1) | SMT201700063B (hr) |
WO (1) | WO2011028933A1 (hr) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003104496A1 (en) * | 2002-06-11 | 2003-12-18 | Idaho Research Foundation | Type i interferon-inducible proteins to detect viral infection |
WO2008070135A2 (en) * | 2006-12-06 | 2008-06-12 | Medimmune, Llc. | Methods of treating systemic lupus erythematosus |
WO2008137838A2 (en) * | 2007-05-03 | 2008-11-13 | Medimmune, Llc | Interferon alpha-induced pharmacodynamic markers |
JP6211513B2 (ja) * | 2011-04-26 | 2017-10-11 | ジェネンテック, インコーポレイテッド | 自己免疫疾患の治療のための組成物及び方法 |
WO2013101771A2 (en) * | 2011-12-30 | 2013-07-04 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
KR20210130270A (ko) | 2012-06-13 | 2021-10-29 | 아스트라제네카 아베 | 항-i형 인터페론 수용체(ifnar) 항체에 대한 고정 투여 계획 |
JP6531306B2 (ja) * | 2015-02-20 | 2019-06-19 | 一三 西野 | 炎症性筋疾患鑑別マーカー及びそれを用いた炎症性筋疾患と非炎症性筋疾患の鑑別方法 |
CN105316404B (zh) * | 2015-02-27 | 2017-02-22 | 中南大学湘雅二医院 | 系统性红斑狼疮生物标志物及其诊断试剂盒 |
MX2018010771A (es) | 2016-03-10 | 2019-05-15 | Viela Bio Inc | Moleculas de union al transcrito 7 similar a inmunoglobulina (ilt7) y metodos de uso de las mismas. |
CN105567861B (zh) * | 2016-03-16 | 2018-12-14 | 宫蕊 | Ifi27作为冠心病诊断标志物的用途 |
WO2020165437A1 (en) * | 2019-02-15 | 2020-08-20 | Astrazeneca Ab | Type i interferon-mediated disorders |
WO2021094378A1 (en) | 2019-11-11 | 2021-05-20 | Astrazeneca Ab | Type i interferon inhibition in systemic lupus erythematosus |
EP4157873A2 (en) | 2020-05-29 | 2023-04-05 | Astrazeneca AB | Treatment of cardiometabolic disease with inhibitors of type i interferon signalling |
TW202237647A (zh) | 2020-10-08 | 2022-10-01 | 瑞典商阿斯特捷利康公司 | 狼瘡發作之治療 |
AU2021383537A1 (en) | 2020-11-18 | 2023-06-29 | Astrazeneca Ab | Steroid sparing |
WO2022223770A1 (en) | 2021-04-23 | 2022-10-27 | Astrazeneca Ab | Treatment of cutaneous lupus erythematous |
KR20240001704A (ko) | 2021-04-23 | 2024-01-03 | 아스트라제네카 아베 | 항-i형 inf 수용체 항체 아니프롤루맙을 이용한 루푸스 신염의 치료 |
JP7484027B2 (ja) | 2021-04-23 | 2024-05-15 | アストラゼネカ・アクチエボラーグ | 皮下注射のための抗ifnar1投薬計画 |
KR20240004451A (ko) * | 2021-05-04 | 2024-01-11 | 비엘라 바이오, 인크. | Ilt7 결합 단백질을 이용한 자가면역 장애의 치료 방법 |
IL308128A (en) | 2021-05-12 | 2023-12-01 | Astrazeneca Ab | Inhibitor of type 1 interferon receptor spares steroids in patients with systemic lupus erythematosus |
TW202340245A (zh) | 2021-07-27 | 2023-10-16 | 瑞典商阿斯特捷利康公司 | 狼瘡之治療 |
CA3233069A1 (en) | 2021-10-04 | 2023-04-13 | Astrazeneca Ab | Treatment of lupus |
WO2024056631A1 (en) | 2022-09-14 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | S1p 1 receptor modulators for use in the treatment of type 1 ifn mediated diseases |
WO2024079241A1 (en) | 2022-10-13 | 2024-04-18 | Astrazeneca Ab | Treatment of lupus |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8303165D0 (en) | 1983-02-04 | 1983-03-09 | Secher D S | Monoclonal antibody |
EP0139676B1 (en) | 1983-02-04 | 1992-11-25 | Cytoclonal Pharmaceutics Inc. | Production and characterization of hybridoma antibodies directed specifically against common determinant(s) present among closely related, but distinct proteins |
DE3306060A1 (de) | 1983-02-22 | 1984-08-23 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Neue immunglobulin-produzierende hybridzellinien, deren verwendung und verfahren zu deren herstellung |
ATE78262T1 (de) | 1985-06-11 | 1992-08-15 | Ciba Geigy Ag | Hybrid-interferone. |
US7247425B2 (en) * | 1998-01-30 | 2007-07-24 | Evolutionary Genomics, Llc | Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions |
US7087726B2 (en) | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
US7749695B2 (en) * | 2003-03-03 | 2010-07-06 | Alexander Abbas | PRO polypeptides for diagnosis of systemic lupus erythematosis |
CA2458085A1 (en) * | 2003-03-21 | 2004-09-21 | F. Hoffmann-La Roche Ag | Transcriptional activity assay |
ES2368737T3 (es) | 2003-04-23 | 2011-11-21 | Medarex, Inc. | Anticuerpos humanizados contra el receptor de interferon alfa 1 (ifnar-1). |
PT1711207E (pt) | 2003-12-10 | 2013-02-13 | Medarex Inc | Anticorpos alfa interferão e seus usos |
WO2005086891A2 (en) * | 2004-03-05 | 2005-09-22 | Rosetta Inpharmatics Llc | Classification of breast cancer patients using a combination of clinical criteria and informative genesets |
AU2005258077C1 (en) | 2004-06-21 | 2012-10-25 | E. R. Squibb & Sons, L.L.C. | Interferon alpha receptor 1 antibodies and their uses |
WO2007019219A2 (en) * | 2005-08-05 | 2007-02-15 | Genentech, Inc. | Methods and compositions for detecting autoimmune disorders |
US8211649B2 (en) * | 2006-03-31 | 2012-07-03 | Human Genome Sciences, Inc. | Methods of diagnosing and prognosing hodgkin's lymphoma |
EP2052088A2 (en) * | 2006-08-02 | 2009-04-29 | Genizon Biosciences | Genemap of the human genes associated with psoriasis |
WO2008070135A2 (en) * | 2006-12-06 | 2008-06-12 | Medimmune, Llc. | Methods of treating systemic lupus erythematosus |
WO2008137838A2 (en) * | 2007-05-03 | 2008-11-13 | Medimmune, Llc | Interferon alpha-induced pharmacodynamic markers |
US20100209914A1 (en) * | 2007-05-25 | 2010-08-19 | Ore Pharmaceuticals , Inc. | Methods, systems, and kits for evaluating multiple sclerosis |
KR20110005783A (ko) * | 2008-02-08 | 2011-01-19 | 메디뮨 엘엘씨 | 질환 마커 및 그의 용도 |
KR20110014979A (ko) * | 2008-04-21 | 2011-02-14 | 노파르티스 포르슝스티프퉁 쯔바이크니덜라쑹 프리드리히 미셔 인스티튜트 포 바이오메디칼 리서치 | 항바이러스 요법 |
US20090325176A1 (en) * | 2008-06-05 | 2009-12-31 | Wyeth | Gene Expression Profiles Associated with Asthma Exacerbation Attacks |
-
2010
- 2010-09-02 RS RS20170089A patent/RS55641B1/sr unknown
- 2010-09-02 LT LTEP10814513.7T patent/LT2473636T/lt unknown
- 2010-09-02 SI SI201031376A patent/SI2473636T1/sl unknown
- 2010-09-02 BR BR112012004781A patent/BR112012004781A2/pt not_active IP Right Cessation
- 2010-09-02 MX MX2012002640A patent/MX2012002640A/es not_active Application Discontinuation
- 2010-09-02 PT PT108145137T patent/PT2473636T/pt unknown
- 2010-09-02 JP JP2012528058A patent/JP5727484B2/ja not_active Expired - Fee Related
- 2010-09-02 ME MEP-2017-24A patent/ME02599B/me unknown
- 2010-09-02 RU RU2012112802/10A patent/RU2012112802A/ru not_active Application Discontinuation
- 2010-09-02 DK DK10814513.7T patent/DK2473636T3/en active
- 2010-09-02 CN CN2010800447566A patent/CN102753704A/zh active Pending
- 2010-09-02 ES ES10814513.7T patent/ES2613055T3/es active Active
- 2010-09-02 US US13/393,616 patent/US20120251546A1/en not_active Abandoned
- 2010-09-02 CA CA2772921A patent/CA2772921A1/en not_active Abandoned
- 2010-09-02 PL PL10814513T patent/PL2473636T3/pl unknown
- 2010-09-02 WO PCT/US2010/047721 patent/WO2011028933A1/en active Application Filing
- 2010-09-02 AU AU2010289383A patent/AU2010289383B2/en not_active Ceased
- 2010-09-02 EP EP10814513.7A patent/EP2473636B1/en active Active
- 2010-09-02 KR KR1020127008547A patent/KR20120101340A/ko not_active Application Discontinuation
- 2010-09-02 HU HUE10814513A patent/HUE032917T2/hu unknown
-
2015
- 2015-03-18 US US14/662,134 patent/US20150191788A1/en not_active Abandoned
- 2015-04-02 JP JP2015075518A patent/JP2015147788A/ja active Pending
- 2015-10-06 US US14/876,549 patent/US20160024205A1/en not_active Abandoned
-
2017
- 2017-01-19 HR HRP20170091TT patent/HRP20170091T1/hr unknown
- 2017-01-26 CY CY20171100112T patent/CY1118566T1/el unknown
- 2017-01-26 SM SM201700063T patent/SMT201700063B/it unknown
Also Published As
Publication number | Publication date |
---|---|
RU2012112802A (ru) | 2013-10-10 |
HUE032917T2 (hu) | 2017-11-28 |
PT2473636T (pt) | 2017-02-06 |
CN102753704A (zh) | 2012-10-24 |
JP2013503642A (ja) | 2013-02-04 |
ME02599B (me) | 2017-06-20 |
US20160024205A1 (en) | 2016-01-28 |
JP2015147788A (ja) | 2015-08-20 |
EP2473636A1 (en) | 2012-07-11 |
EP2473636A4 (en) | 2013-02-27 |
SMT201700063B (it) | 2017-03-08 |
SI2473636T1 (sl) | 2017-04-26 |
US20120251546A1 (en) | 2012-10-04 |
LT2473636T (lt) | 2017-02-10 |
CY1118566T1 (el) | 2017-07-12 |
EP2473636B1 (en) | 2016-10-26 |
RS55641B1 (sr) | 2017-06-30 |
KR20120101340A (ko) | 2012-09-13 |
WO2011028933A1 (en) | 2011-03-10 |
CA2772921A1 (en) | 2011-03-10 |
AU2010289383B2 (en) | 2015-04-16 |
MX2012002640A (es) | 2012-06-25 |
ES2613055T3 (es) | 2017-05-22 |
PL2473636T3 (pl) | 2017-05-31 |
AU2010289383A1 (en) | 2012-04-19 |
JP5727484B2 (ja) | 2015-06-03 |
BR112012004781A2 (pt) | 2017-02-14 |
DK2473636T3 (en) | 2017-02-06 |
US20150191788A1 (en) | 2015-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20170091T1 (hr) | Dijagnostika interferona tip 1 | |
JP2013503642A5 (hr) | ||
KR102642854B1 (ko) | 췌장암의 검출 키트 또는 디바이스 및 검출 방법 | |
KR102646601B1 (ko) | 간암의 검출 키트 또는 디바이스 및 검출 방법 | |
KR102511713B1 (ko) | 대장암의 검출 키트 또는 디바이스 및 검출 방법 | |
JP2019196400A5 (hr) | ||
JP2012518421A5 (hr) | ||
KR20170018406A (ko) | 식도암의 검출 키트 또는 디바이스 및 검출 방법 | |
WO2010017515A2 (en) | Breast cancer specific markers and methods of use | |
JP2011511804A5 (hr) | ||
JP2012533322A5 (hr) | ||
JP2013178260A5 (hr) | ||
CN106319089B (zh) | lncRNA在缺血性脑卒中诊断中的应用 | |
KR101263622B1 (ko) | 고혈압 감수성 유전자군의 동정 | |
CN106337089A (zh) | 一种用于缺血性脑卒中诊断的lncRNA | |
JP2022130509A (ja) | 分析方法及びキット | |
CN106555004A (zh) | 缺血性脑卒中的lncRNA标志物 | |
JP2011211955A (ja) | 肝ガン患者予後予測用組成物及び方法 | |
EP2062983A3 (de) | Primer und Sonden zum Nachweis genitaler HPV-Genotypen | |
JP5757032B2 (ja) | miRNAを利用した慢性肝疾患の線維化の検査方法 | |
JP2006520587A5 (hr) | ||
CN103834730A (zh) | Zfp28的变异位点在制备诊断精神分裂症的试剂盒中的用途 | |
KR20210131242A (ko) | 상향조절된 mirna의 진단 및 치료를 위한 용도 | |
KR102680815B1 (ko) | 췌장암의 검출 키트 또는 디바이스 및 검출 방법 | |
KR102679429B1 (ko) | 간암의 검출 키트 또는 디바이스 및 검출 방법 |